Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sankyo, Kowa: AII Receptor Blocker Olmetec
May 24, 2004
- Eli Lilly Japan, Chugai: Evista for Postmenopausal Osteoporosis
May 24, 2004
- Kissei, Takeda: Glufast Tab
May 24, 2004
- Novartis: Visudyne for AMD
May 24, 2004
- BUSINESS NEWS IN BRIEF
May 24, 2004
- WEBSITE NEWS
May 24, 2004
- MR-kun Used by 76% of Physicians when Prescribing: So-net M3 Survey
May 24, 2004
- REGULATORY NEWS IN BRIEF
May 24, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 24, 2004
- 1st Pharmacogenomics Study Initiated in Japan on Aspirin
May 24, 2004
- Business Restructuring to Bolster R&D, MR Force: Daiichi
May 24, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
May 24, 2004
- WORLD NEWS IN BRIEF
May 24, 2004
- DIAGNOSTIC NEWS IN BRIEF
May 24, 2004
- WEBSITE NEWS
May 17, 2004
- Korosho, Monkasho Hold Hearings on Clinical Trial Promotion Plan
May 17, 2004
- REGULATORY NEWS IN BRIEF
May 17, 2004
- WORLD NEWS IN BRIEF
May 17, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 17, 2004
- NBI, Yamanouchi Aim at Early Achievement of \40 Bil. Sales for Micardis
May 17, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…